

USE OF FROMILID® UNO IN TREATMENT OF PATIENTS WITH MILD COMMUNITY-ACQUIRED PNEUMONIA

T. A. Pertseva, V. V. Dmytrychenko

Summary

The results of application of Fromilid® uno in treatment of 25 patients with mild community-acquired pneumonia. It was established that clarythromycin in slow-released formulation (Fromilid® uno) had good clinical and bacteriological efficacy in patients with mild community-acquired pneumonia.

The results of the study confirmed adequacy of Fromilid® uno 1000 mg once daily regimen in treatment of patients with mild community-acquired pneumonia.